Compare LQDA & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | PBH |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | 600 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 3.0B |
| IPO Year | 2018 | 2005 |
| Metric | LQDA | PBH |
|---|---|---|
| Price | $35.14 | $61.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | $37.40 | ★ $86.40 |
| AVG Volume (30 Days) | ★ 1.7M | 439.1K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.04 |
| Revenue | $69,216,000.00 | ★ $1,110,479,000.00 |
| Revenue This Year | $904.79 | N/A |
| Revenue Next Year | $188.25 | $2.50 |
| P/E Ratio | ★ N/A | $15.20 |
| Revenue Growth | ★ 343.41 | N/A |
| 52 Week Low | $10.37 | $57.25 |
| 52 Week High | $35.54 | $90.04 |
| Indicator | LQDA | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 67.11 | 56.46 |
| Support Level | $32.11 | $59.52 |
| Resistance Level | $35.54 | $62.40 |
| Average True Range (ATR) | 1.50 | 1.44 |
| MACD | -0.05 | 0.32 |
| Stochastic Oscillator | 92.26 | 79.01 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.